"Scientifically this type of a 'trial' would be worthless. What if patients who are col24a1 WT naturally progress more slowly than those who are variant. Then the WT patients would do better than variant regardless of treatment (Blarca, MAb, donepezil, KoolAid)."
I wasn't actually suggesting it as a trial but could still be notable if access ad again finds col24a1wt are doing better with blarcamesine with again better brain preservation (and it's established there is no reason for them to naturally do better).
The UK bio bank alone has genome data for around 500k people - around 2,800 who have/had AD.
There would not be perfect AD data but you could look at the mortality data as objective measure.
That's just UK there would be lots of other biobanks so knowing if it was actually the case that col24a1wt patients naturally did better in AD and to what extent would be fairly easy to find out.
Market Data 
Markets 
AI
